retinal ganglion cells with large somata and large-diameter axons, which correspond to the magnocellular visual pathway, may show an increased vulnerability, although this has been questioned. 3 One pOSSible cause of the death of ganglion cells is mechanical damage and/ or ischaemic damage to their axons at the level of the lamina crib rosa induced by either elevated intraocular pressure (lOP) or altered blood flow. Another possible cause may be related to the finding that glutamate levels in the vitreous humour of glaucoma patients are elevated. 4 This glutamate could have originated from an injured retina, such as one that had experienced an ischaemic-like insult (hypoxia/ anoxia) caused by reduced blood flow or raised lOP . An insult of this nature, which leads to the release of glutamate, would make retinal neurone-types (ganglion cells and a subset of amacrine cells) that contain ionotropic glutamate receptors particularly vulnerable. Anatomical studies on retinas of glaucoma patients support the opinion that both ganglion cells and certain amacrine cells are particularly affected (see review by Osborne et aI.5). In experimental ischaemia, glutamate is released from the retina 6 • 7 and causes destruction of ganglion and some amacrine cells. s The released glutamate may well accumulate in the vitreous humour.
Chronic glaucoma, for which the model is primary open-angle glaucoma (POAG), is perhaps best defined as a heterogeneous group of disorders with a distinctive type of optic nerve damage and characteristic form of field loss. The major causes of glaucoma are likely to be hypoxia/anoxia (affected ocular blood supply to optic nerve head) and/ or raised lOP. Therefore, the ideal drug for treatment of glaucoma is a substance which, when topically applied, reduces raised lOP, facilitates ocular blood flow in the optic nerve head and protects the retina from destruction. 9 Experimental studies on animals now give us good reason to believe that certain members of two classes of substances -l3-blockers (e.g. betaxolol) and serotonin (5-hydroxytryptamine; 5-HT) 5-HT 1A receptor agonists (e.g. 8-hydroxy-2-(di-N propylamino)tetralin or 8-0H-DPAT and flesinoxan) -may fulfil these criteria. Betaxolol 2.5 X 10-1 0 3.3 X 10-10 4.9 X 10-1 0 2.5 X 10-9 3.6 X 10-9 > 1.0 X 10-4 > 1.0 X 10 -4
Data are mean ± SEM value for three or four experiments. 8-0H-DPAT was originally thought to be a very selective 5-HT lA agonist 23 but subsequently has been shown to have some affinity for the 5-HT 7 receptor. 24 8-0H-DPAT when applied topically to the rabbit eye reduces lOP in both the light and dark. 25 , 2 6 The full 5-HT 1 A agonist (+)8-0H-DPAT is a more effective hypotensive agent than the partial agonist (-)8-0H-DPAT (Fig. 3) , and this result when taken with the finding that the effect of (±)8-0H-DPAT on lOP was blocked by pretreatment with pindolol, a mixed 5-HTIA antagonist/j3-blocker, but not by the specific j3-blocker betaxolol, suggests that 8-0H-DPAT lowers lOP via activating 5-HT 1 A receptors ( Studies with ketanserin also suggest that antagonists of 5-HT 2 receptors, when applied topically, can lower lOP. For example, topically applied ketanserin lowers lOP in the rabbit 21 and in man. 2 8 , 29 It should, however, be borne in mind that ketanserin is known to have an affinity for CXl adrenoceptors 27 and for this reason the effects of ketanserin on lOP may not be entirely caused by its effect on 5-HT 2 receptors. Additional studies need to be conducted with specific 5-HT 2 ligands to clarify the situation.
Serotonin receptors in the retina
The evidence for serotonin being a neurotransmitter in the mammalian retina (as opposed to the non mammalian retina) remains a matter of debate because there is a lack of clear data showing the existence of serotonergic neurones ? D , 31 However, numerous studies have shown serotonin receptors to be associated with mammalian retinas. Using radiolabelled serotonin or its analogues, saturable 5-HT binding sites were shown to be associated with the retina; 32 moreover, multiple 5-HT receptor subclasses were identified in the rabbit retina, including 5-HTI-like and 5-HT 2 33 and 5-HT 3 . 34 Secondary messenger studies also showed that serotonin increased cAMp 35 , 3 6 and inositol phosphate production, 37 , 3 8 demonstrating that retinal 5-HT receptors are coupled functionally to their known effector systems. At the time it was thought that the serotonergic receptors in the rabbit retina belonged to the 5-HT'A subtype because of the pharmacological profile of the observed response. However, although early studies indicated that 5-HTIA receptors can both stimulate 39 and inhibit 40 adenylate cyclase, it is now widely accepted that 5-HT1A-like stimulations in cAMP production are mediated not through 5-HTIA receptor activation but via the operationally similar 5-HT 7 subtype. Thus the increase in cAMP found in retinal tissue following application of serotonin is most likely due to activation of 5-HT 7 receptors, which are preferentially linked to an increase in cAMP synthesis. Support for this opinion has come from recent work which established the presence of 5-HT 7 mRNA 1 8 and 5-HT ,like binding sites in the rabbit retina (Figs. 1, 2) .
Although 5-HT 1 A receptors were not detected in rabbit retina it could equally not be concluded that they are absent, and indeed, preliminary RT-PCR data indicate that 5-HTIA mRNA is present in human retina. Neuropharmacological studies suggest that activation of 5-HTIA' 5-HT 2 A and 5-HT 3 receptors affect visual processing 41 -43 and 5-HT 2 A receptors are associated with terminals of the photoreceptors and rod bipolar cells in the rabbit retina. 44 However, as far as the other serotonin receptors are concerned (5-HTIA' 5-HT 3 and 5-HT 7 receptors), no information exists on their distribution in the retina. In the context of glaucoma we therefore have no definitive evidence for ganglion cells containing a particular type of serotonin receptor.
Neuroprotective action of 5-HT1A agonists
The direct neuroprotective action of 5-HTIA agonists was demonstrated by use of confluent rat cortical cultures, which were prepared as previously described. 45 The cultures in serum-free medium were exposed to glutamate (100 f.lM) either alone or together with a 5-HTIA agonist (100 f.lM flesinoxan or 8-0H-DPAT) for 4 h under normotoxic conditions. In other experiments the cultures were subjected to hypoxic conditions, 95% N 2 /5%C0 2 , for 5 ha t 37°C with 5-HTIA agonists added before hypoxia where appropriate: reoxygenation was achieved by re-placing the cells in normoxic conditions for 3 h before analyses. Cellular injury (due to L-glutamate or hypoxia/normoxia) was assessed by measurement of lactate dehydrogenase (LDH) release into the cell culture medium. 45 As shown in Table 4 both flesinoxan and 8-0H-DP AT significantly counteracted the effect of L-glutamate or hypoxia/reperfusion. The 5-HTIA antagonist/l3-blocker, propranolol (5 f.lM), did not counteract the effect of flesinoxan or 8-0H-DPAT (Table 4) . However, since propranolol had a protective effect on its own (Table 4) (probably because of its calcium channel blocking properties 4 6 ), these experiments could not determine whether the effects of flesinoxan and 8-0H-DPAT are via activation of 5-H T1A receptors. 
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CiI To test the general neuroprotective properties of 8-0H-DPAT on the rabbit retina in vivo, 8-0H-DPAT was injected directly twice into the vitreous humour (concentration in the vitreous humour on each occasion 100 fLM) of one eye, once just before ischaemia and then at the onset of reperfusion. Control animals received injections of vehicle in one eye. Ischaemia was induced in the injected eye by raising the lOP above the systolic blood pressure using a suction-cup procedure 47 for 60 min. Three days after ischaemia (the reperfusion period) the electroretinogram (ERG) was recorded from both eyes and the amplitude of the b-wave determined. The animals were then killed and sections of the retinas 'stained' for the localisation of choline acetyltransferase (ChAT) and parvalbumin immunoreactivities. Ischaemia/reperfusion causes a reduction of the b-wave (Fig. 6 ) and changes in the ChAT and parvalbumin immunoreactivities (Fig. 7) . 8-0H-DP AT significantly counteracted the effects of ischaemia/reperfusion so that the nature of the b-wave and the staining of the ChAT and parvalbumin appeared more normal (Figs. 6, 7) .
In 1982 we showed that the antigen Thy-1 is localised to ganglion cells 4 8 and subsequent studies have deduced that ischaemia/reperfusion to the rat retina causes destruction of the ganglion cells and loss of the mRNA 49 and the antigen 50 for Thy-I. By quantifying the mRNA for Thy-1 in the whole of the retina and relating the content to other retinal mRNAs (cyclophilin, rhodopsin) an assay for ganglion cell survival was constructed. 49 As shown in Fig. 8 , intravitreal injection of N-methyl-D aspartate (NMDA; 20 nmol) to the rat retina causes a significant reduction in retinal Thy-1 mRNA level relative to cyclophilin, while this is not the case for rhodopsin mRNA. However, when 8-0H-DPAT (20 nmol) is co-injected into the vitreous humour (to give a concentration of 200 fLM in the vitreous humour) at the same time as NMDA the reduction in the retinal Thy-l mRNA level is significantly attenuated (Fig. 8) .
We conclude from such experiments that NMDA induced toxicity to the ganglion cells is attenuated by 8-0H-DPAT.
Our most recent studies show that 8-0H-DPAT can act as a retinal neuroprotectant even when applied topically to the eye. It is assumed that the topically Table 4 . The effect of 8-0H-DPAT, f/esinoxan, propranolol and MK-801 on the glutamate and hypoxialreperfusion-induced release of lactic dehydrogenase (LDH) applied drug reaches the retina through the systemic system, as this appears to be the case in experiments where betaxolol was used. ll In these experiments, the drug (or vehicle) was topically applied (5 j-Ll of 0.5% solution) 10 min and 5 min before ischaemia, directly after ischaemia and then daily during reperfusion. The b-wave of the ERG was also measured at 2 and 5 days during reperfusion. Fig. 9 shows that the b-wave of the ERG in the 8-0H-DPAT treated animals is significantly less reduced (n = 4) than in those animals which received vehicle, thus suggesting a 'protection' against ischaemia/ reperfusion. Moreover, the ChAT immunoreactivity (5 days follOWing reperfusion) was completely obliterated in retinas which received ischaemia in all vehicle-treated animals (n = 4) but traces of ChAT immunoreactivity were evident in three of the four animals which received 8-0H-DPAT (Fig. 10 ).
Neuroprotective mode of action of 8-0H-DP AT 8-0H-DPAT is a potent agonist at 5-HT 1 A and a partial agonist at 5-HT 7 receptors, 24 and both receptor-types exist in the mammalian retina (see above). Thus the neuroprotective effect of 8-0H-DPAT on ischaemia/ reperfusion or NMDA-induced effects on the b-wave of the ERG, ChAT and parvalbumin immunoreactivities and ganglion cell Thy-1 mRNA levels may be mediated via an action on 5-HT 1 A and/or 5-HT 7 receptors. Studies on brain tissues have demonstrated that neuroprotection can be induced by activation of 5-HT 1 A receptors. 5 1 , 52 However, in our studies we could not draw such a conclusion because we did not blunt the neuroprotective effects of 8-0H-DPAT with propranolol. In addition, propranolol is not a very effective 5-HTIA antagonist and more selective and specific antagonists need to be tested.
Laboratory studies show that there are various ways of attenuating neuronal death caused by ischaemia/ reperfusion. 5 Substances, for example, which prevent an unusual rise in calcium and/or free radicals in an insulted neurone are likely to act as neuroprotectants. 5 Although we have not tested whether 8-0H-DPAT acts as a free radical scavenger, studies have been conducted to determine whether it can act as a 'calcium channel blocker'. Initial experiments were carried out on rat cortical cultures as described elsewhere. 53 The cortical cultures in a medium containing 45 Ca 2+ are exposed to either to NMDA alone or in combination with 8-0H-DP A T. As shown in Table 5 , NMOA stimulates an influx of 45 Ca 2+ into the neurones and 100 j-LM 8-0H-OPAT causes a significant attenuation. Similar results have been generated with betaxolol Y We next investigated whether 8-0H-OP AT has an affinity for the L-type calcium channel using a radioactive binding procedure described elsewhere. 4 6 Surprisingly, 8-0H-OPAT had very little affinity for the L-type calcium channel (Fig. 11) . Since betaxolol binds to the
0.0 Fig. 6 . Two groups of animals (n = 5) were used. The right eye of one group received 10 ILl saline before and after ischaemia; the left eye received 8-0H-DPAT (final concentration in vitreous humour estimated to be 100 ILM) at the same times. The left eye of both groups of animals received ischaemia with a suction methodology for 60 min. The amplitudes of the b-wave of the electroretinogram was determined 3 days after ischaemia, i.e. following 3 days of reperfusion. It can be seen that administration of 8-0H-DPAT attenuates the reduction in the b-wave relative to the control. *p < 0.05 compared with control; **p < 0.05 compared with ischaemia. Densitometric readings for Thy-l and rhodopsin mRNA species were calculated relative to cyclophilin mRNA levels and expressed as percentages of control amounts in each case. Note that rhodopsin mRNA is unaffected by NMDA whereas this compound leads to a significant reduction in Thy-1 mRNA, which is partially ameliorated by 8·0H·DPAT. *p < 0.05, compared with control vehicle injected values using paired Student's t·test (n = 4); **p < 0.05, compared with values obtained for NMDA-treated retinas using paired Student's t-test (n = 4).
other type(s) of calcium channels, such as N-, P /Q-or T-.
Another possibility is that it acts directly at 5-HT l A receptors situated on the cortical neurones. However, spiroxatrine (a putative 5-HT 1 A antagonist) did not blunt the effect of 8-0H-DP AT on the NMDA-induced influx of calcium, which does not support this idea (see Table 5 ). following ischaemia. It can be seen that the b-wave recovery of untreated animals following ischaemia and reperjusion times of 2 and 5 days is around 15%. In the 8-0H-DPAT treated animals the recovery at 2 days is around 30% and at 5 days greater than 50%. *p < 0.05 compared with t = 0; **p < 0.05 compared with control. Immunoreactivity is associated with two bands of fibres in the inner plexiform layer (small arrows) and perikarya on each side (large arrows). Following ischaemia/reperjusion most of the ChAT immunoreactivity is obliterated (B). However, when animals are treated topically with 8-0H-DPAT, the ischaemia/reperfusion-induced eff ect on the ChAT immunoreactivity is partially blunted with some ChAT 'staining' still apparent (C).
Recent studies have shown that substances which reduce sodium influx into neurones are also neuroprotective. 54 The neuroprotection may occur by indirectly reducing calcium influx; nevertheless, good evidence exists which demonstrates that activation of voltage-sensitive sodium channels (VSSCs) is involved in the pathophysiology of ischaemic damage. There are three major types of VSSCs in the brain, termed Rat I, Rat II and Rat III, which are responsible for the generation of action potentials in excitable membranes. Several neurotoxins are known to bind with high affinity to specific sites on these VSSCs and alter channel function. Five classes of these neurotoxin binding sites are currently recognised (neurotoxin sites 1-5), the most important of which are sites 1 and 2. Site 1 is located in the vestibule of the channel at the selectivity filter and binding of toxins such as tetrodotoxin and saxitoxin directly blocks the passage of Na + ions through the channel. Conversely, site 2 is found in the transmembrane region and is involved in the gating of the channel. Lipid-soluble toxins including veratridine and batrachotoxin bind at site 2 causing a persistent activation of the sodium channel, which can be reversed by tetrodotoxin in a non-competitive fashion. Several local anaesthetics, antiarrhythmics and anticonvulsants inhibit neuronal excitability by interacting with VSSCs at (n = 14) (n = 5) (n = 9) (n = 6) (n = 4) (Fig. 12) . Our latest preliminary data indicate that this interaction is inhibitory, since the influx of 22 Na + into rat cortical synaptosomes induced by veratridine was dose-dependently attenuated by both 8-OH-DPAT and flesinoxan (data not shown).
Conclusions
It is generally agreed that disturbances of ocular blood flow (vascular dysregulation, perfusion pressure changes) and/or lOP is/are involved in the pathogenesis of glaucoma. It is also probable that other factors (age, genes, diet, endocrine abnormalities) may play a part. In any event, it is the death of the ganglion cells that leads to loss of vision. Clearly any drug which reduces the rate of ganglion cell death in glaucoma, irrespective of how death may have occurred, will theoretically benefit a glaucoma patient. If such a drug can additionally reduce the one risk factor that is measurable, i.e. raised lOP, and also possibly facilitate ocular blood flow then the drug in question is potentially important. If the drug can also be tolerated by the patient as well as reaching the retina when applied topically then the criteria for the ideal glaucoma drug are approached.
Many 5-HT lA agonists are used in the treatment of depression so they can be reasonably tolerated by patients. Moreover, 5-HT 1 A agonists such as urapidil are known to dilate blood vessels, so theoretically could stimulate ocular blood flow. Our studies have shown that 5-HT 1 A agonists (8-0H-DPAT and flesinoxan) reduce lOP in rabbits. Moreover, we show that 8-0H-DPAT blunts the effects of insults (NMDA toxicity, ischaemia/ reperfusion) to the retinas of animals. The neuroprotective effect of 8-0H-DPAT involves reducing the influx of sodium but it may also involve interaction with retinal 5-HTIA and/or 5-HT 7 receptors, although this remains to be demonstrated. Thus it is proposed that 5-HT lA agonists need to be considered as a class of drugs for the treatment of glaucoma.
